Maspin expression in endometrial hyperplasia and carcinoma, and its relation with angiogenesis

Aim: The purpose of this study was to evaluate the maspin expression in endometrial hyperplasia and cancer, and also to investigate its relation with angiogenesis. Materials and Methods: A total of 19 women with complex atypical hyperplasia, 44 patients with simple hyperplasia without atypia, and 67 patients with endometrial carcinoma were included. Maspin expression was assessed by immunohistochemistry (IHC), and tested for possible significant relation with age, FIGO stage, histologic type, grade, depth of myometrial invasion (MI), lymphovascular space involvement (LVSI), lymph node metastasis, and overall survival (OS). Angiogenesis was determined by vascular endothelial growth factor (VEGF) staining. Results: Maspin expression was detected in only three patients with endometrial hyperplasia (5%). In patients with endometrial cancer, cytoplasmic and nuclear maspin expressions were detected in 36 (53.7%) and 18 (26.9%) patients, respectively. No significant relation was noted between staining localizations and prognostic variables. The five-year OS rate for patients with cytoplasmic staining was 91%, compared to 87% for patients without staining (p = 0.31). These values for nuclear expression were 100% and 87%, respectively (p = 0.16). The cytoplasmic and nuclear maspin expressions were found to be significantly correlated with VEGF (r = 0.278, p = 0.02 and r = 0.295, p = 0.01, respectively). Discussion: This is the first study to demonstrate the relation between maspin expression and angiogenesis in endometrial cancer. Although no survival difference was noted for cytoplasmic or nuclear maspin expressions, a tendency was detected for nuclear staining. Further series will clarify the exact prognostic role of maspin expression in gynecological malignancies including endometrial cancer.

Maspin; Endometrial cancer; Endometrial hyperplasia; Angiogenesis; Survival.

[1] Zou Z., Anisowicz A., Hendrix M.J. Thor A., Neveu M., Sheng S., et al.: “Maspin, a serpin with tumor suppressing activity in human mammary epithelial cells”. Science, 1994, 263, 526.

[2] Sheng S., Pemberton P.A., Sager R.: “Production, purification, and characterization of recombinant maspin proteins”. J. Biol. Chem., 1994, 269, 30988.

[3] Sheng S., Carey J., Seftor E.A. Dias L., Hendrix M.J., Sager R.: “Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells”. Proc. Natl. Acad. Sci USA, 1996, 93, 11669.

[4] Maass N., Hojo T., Ueding M., Lüttges J., Klöppel G., Jonat W., Nagasaki K.: “Expression of the tumor suppressor gene Maspin in human pancreatic cancers”. Clin. Cancer Res., 2001, 7, 812.

[5] Schneider S.S., Schick C., Fish K.E. Miller E., Pena J.C., Treter S.D.: “A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene”. Proc. Natl. Acad. Sci. USA, 1995, 92, 3147.

[6] Zhang M., Maass N., Magit D., Sager R.: “Transactivation through Ets and Ap1 transcriptional sites determines the expression of the tumor-suppressing gene maspin”. Cell Growth Differ., 1997, 8, 179.

[7] Pemberton P. Maspin: Functional insights from a structural perspective. In: Hendrix MJ, editor. Maspin. Iowa City, 2002.

[8] Pemberton P.A., Tipton A.R., Pavloff N., Smith J., Erickson J.R., Mouchabeck Z.M., Kiefer M.C.: “Maspin is an intracellular serpin that partitions into secretory vesicles and is present at the cell surface”. J. Histochem. Cytochem., 1997, 45, 1697.

[9] Abraham S., Zhang W., Greenberg N., Zhang M.: “Maspin functions as a tumor suppressor by increasing cell adhesion to extracellular matrix in prostate tumor cells”. J. Urol., 2003, 169, 1157.

[10] Sood A.K., Fletcher M.S., Gruman L.M. Coffin J.E., Jabbari S., Khalkhali-Ellis Z., et al.: “The paradoxical expression of maspin in ovarian carcinoma”. Clin. Cancer Res., 2002, 8, 2924.

[11] Gynecologic Oncology Group; Secord A.A., Lee P.S., Darcy K.M. Havrilesky L.J., Grace L.A., Marks J.R., Berchuck A.: “Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study”. Gynecol. Oncol., 2006, 101, 390.

[12] Solomon L.A., Munkarah A.R., Schimp V.L. Arabi M.H., Morris R. T., Nassar H., Ali-Fehmi R.: “Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer”. Gynecol. Oncol., 2006, 101, 385.

[13] Surowiak P., Materna V., Drag-Zalesinska M., Wojnar A., Kaplenko I., Spaczynski M., et al.: “Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates”. Int. J. Gynecol. Pathol., 2006, 25, 131.

[14] Xu C., Quddus M.R., Sung C.J. Steinhoff M.M., Zhang C., Lawrence W. D.: “Maspin expression in CIN 3, microinvasive squamous cell carcinoma, and invasive squamous cell carcinoma of the uterine cervix”. Mod. Pathol., 2005, 18, 1102.

[15] Murai S., Maesawa C., Masuda T., Sugiyama T.: “Aberrant maspin expression in human endometrial cancer”. Cancer Sci., 2006, 97, 883.

[16] Li H.W., Leung S.W., Chan C.S., Yu M.M., Wong Y.F.: “Expression of maspin in endometrioid carcinoma of endometrium”. Oncol. Rep., 2007, 17, 393.

[17] Folkman J.: “What is the evidence that tumors are angiogenesis de-pendent?”. J. Natl. Cancer Inst., 1990, 82, 4.

[18] Hanahan D., Folkman J.: “Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis”. Cell., 1996, 86, 353.

[19] Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M.: “Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis”. Am. J. Pathol., 1995, 146, 1029.

[20] Zou Z., Gao C., Nagaich A.K. Connell T., Saito S., Moul J.M., et al.: “p53 regulates the expression of the tumor suppressor gene maspin”. J. Biol. Chem., 2000, 275, 6051.

[21] Boltze C., Schneider-Stock R., Quednow C., Hinze R., Mawrin C., Hribaschek A., et al.: “Silencing of the maspin gene by promoter hypermethylation in thyroid cancer”. Int. J. Mol. Med., 2003, 12, 479.

[22] YatabeY., Mitsudomi T., Takahashi T.: “Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation”. Onco-gene, 2003, 23, 4041.

[23] Akiyama Y., Maesawa C., Ogasawara S., Terashima M., Masuda T.: “Celltype-specific repression of the maspin gene is disrupted frequently by demethylation at the promoter region in gastric intestinal metaplasia and cancer cells”. Am. J. Pathol., 2003, 163, 1911.

[24] Mueller E., Sarraf P., Tontonoz P., Evans R.M., Martin K.J., Zhang M, et al.: “Terminal differentiation of human breast cancer through PPAR gamma”. Mol. Cell., 1998, 1, 465.

[25] Jiang W.G., Hiscox S., Horrobin D.F., Bryce R.P., Mansel R.E., “Gamma linolenic acid regulates expression of maspin and the motility of cancer cells”. Biochem. Biophys Res. Commun., 1997, 237, 639.

[26] Hirai K., Koizumi K., Haraguchi S. Hirata H., Mikami I., Fukushima M., et al.: “Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer”. Ann. Thorac. Surg., 2005, 79, 248.

[27] Marioni G., Blandamura S., Giacomelli L., Calgaro N., Segato P., Leo G., et al.: “Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease-free interval after surgery for squamous cell carcinoma of the larynx”. Histopathology, 2005, 46, 576.

[28] Boltze C., Schneider-Stock R., Quednow C., Gerlach R., Mawrin C., Hinze R., et al.: “Proteome analysis identified maspin as a special feature of papillary thyroid carcinoma”. Int. J. Oncol., 2003, 23, 1323.

[29] Mohsin S.K., Zhang M., Clark G.M., Craig Allred D.: “Maspin expression in invasive breast cancer: association with other prognostic factors”. J. Pathol., 2003, 199, 432.

[30] Smith S.L.,Watson S.G., Ratschiller D., Gugger M., Betticher D.C., Heighway J.: “Maspin – The most commonly expressed gene of the 18q21.3 serpin cluster in lung cancer – Is strongly expressed in pre-neoplastic bronchial lesions”. Oncogene, 2003, 22, 8677.

[31] Boltze C., Schneider-Stock R., Meyer F., Gugger M., Betticher D.C., Heighway J.: “Maspin in thyroid cancer: its relationship with p53 and clinical outcome”. Oncol. Rep., 2003, 10, 1783.

[32] Zhang M., Volpert O., Shi Y.H., Bouck N.: “Maspin is an angiogenesis inhibitor”. Nat. Med., 2000, 6, 196.

[33] Wang M.C., Yang Y.M., Li X.H., Dong F., Li Y.: “Maspin expression and its clincopathological significance in tumorigenesis and progression of gastric cancer”. World J. Gastroentereol., 2004, 10, 634.

[34]Song S.Y., Lee S.K., Kim D.H., Son H.J., Kim H.J., Lim Y.J., et al.: “Expression of maspin in colon cancers: its relationship with p53 expression and microvessel density”. Dig. Dis. Sci., 2002, 47, 1831.